BACKGROUND AND PURPOSE: Products of Maillard reactions between aminoacids and reducing sugars are known to have anti-inflammatory properties. Here we have assessed the anti-arthritis effects of (E)-2,4-bis(p-hydroxyphenyl)-2-butenal and its possible mechanisms of action. EXPERIMENTAL APPROACH: We used cultures of LPS-activated macrophages (RAW264.7 cells) and human synoviocytes from patients with rheumatoid arthritis for in vitro assays and the collagen-induced arthritis model in mice. NO generation, iNOS and COX2 expression, and NF-κB/IKK and STAT3 activities were measured in vitro and in joint tissues of arthritic mice, along with clinical scores and histopathological assessments. Binding of (E)-2,4-bis(p-hydroxyphenyl)-2-butenal to STAT3 was evaluated by a pull-down assay and its binding site was predicted using molecular docking studies with Autodock VINA. KEY RESULTS: (E)-2,4-bis(p-hydroxyphenyl)-2-butenal (2.5-10 μg·mL(-1) ) inhibited LPS-inducedNO generation, iNOS and COX2 expression, and NF-κB/IKK and STAT3 activities in macrophage and human synoviocytes. This compound also suppressedcollagen-induced arthritic responses in mice by inhibiting expression of iNOS and COX2, and NF-κB/IKK and STAT3 activities; it also reduced bone destruction and fibrosis in joint tissues. A pull-down assay showed that (E)-2,4-bis(p-hydroxyphenyl)-2-butenal interfered with binding of ATP to STAT3. Docking studies suggested that (E)-2,4-bis(p-hydroxyphenyl)-2-butenal bound to the DNA-binding interface of STAT3 possibly inhibiting ATP binding to STAT3 in an allosteric manner. CONCLUSIONS AND IMPLICATIONS: (E)-2,4-bis(p-hydroxyphenyl)-2-butenal exerted anti-inflammatory and anti-arthritic effects through inhibition of the NF-κB/STAT3 pathway by direct binding to STAT3. This compound could be a useful agent for the treatment of arthritic disease.
BACKGROUND AND PURPOSE: Products of Maillard reactions between aminoacids and reducing sugars are known to have anti-inflammatory properties. Here we have assessed the anti-arthritis effects of (E)-2,4-bis(p-hydroxyphenyl)-2-butenal and its possible mechanisms of action. EXPERIMENTAL APPROACH: We used cultures of LPS-activated macrophages (RAW264.7 cells) and human synoviocytes from patients with rheumatoid arthritis for in vitro assays and the collagen-induced arthritis model in mice. NO generation, iNOS and COX2 expression, and NF-κB/IKK and STAT3 activities were measured in vitro and in joint tissues of arthritic mice, along with clinical scores and histopathological assessments. Binding of (E)-2,4-bis(p-hydroxyphenyl)-2-butenal to STAT3 was evaluated by a pull-down assay and its binding site was predicted using molecular docking studies with Autodock VINA. KEY RESULTS:(E)-2,4-bis(p-hydroxyphenyl)-2-butenal (2.5-10 μg·mL(-1) ) inhibited LPS-inducedNO generation, iNOS and COX2 expression, and NF-κB/IKK and STAT3 activities in macrophage and human synoviocytes. This compound also suppressedcollagen-induced arthritic responses in mice by inhibiting expression of iNOS and COX2, and NF-κB/IKK and STAT3 activities; it also reduced bone destruction and fibrosis in joint tissues. A pull-down assay showed that (E)-2,4-bis(p-hydroxyphenyl)-2-butenal interfered with binding of ATP to STAT3. Docking studies suggested that (E)-2,4-bis(p-hydroxyphenyl)-2-butenal bound to the DNA-binding interface of STAT3 possibly inhibiting ATP binding to STAT3 in an allosteric manner. CONCLUSIONS AND IMPLICATIONS: (E)-2,4-bis(p-hydroxyphenyl)-2-butenal exerted anti-inflammatory and anti-arthritic effects through inhibition of the NF-κB/STAT3 pathway by direct binding to STAT3. This compound could be a useful agent for the treatment of arthritic disease.
Authors: H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne Journal: Nucleic Acids Res Date: 2000-01-01 Impact factor: 16.971
Authors: Jin A Kim; Hyung-Mun Yun; Peng Jin; Hee Pom Lee; Jin Yi Han; Venkatareddy Udumula; Dong Cheul Moon; Sang Bae Han; Ki Wan Oh; Young Wan Ham; Heon-Sang Jung; Ho Sueb Song; Jin Tae Hong Journal: Neuropharmacology Date: 2013-07-23 Impact factor: 5.250
Authors: Dong Ju Son; Dae Hwan Kim; Seong-Su Nah; Mi Hee Park; Hee Pom Lee; Sang Bae Han; Udumula Venkatareddy; Benjamin Gann; Kevin Rodriguez; Scott R Burt; Young Wan Ham; Yu Yeon Jung; Jin Tae Hong Journal: Sci Rep Date: 2016-11-15 Impact factor: 4.379
Authors: Yu Yeon Jung; Dong Ju Son; Hye Lim Lee; Dae Hwan Kim; Min Jong Song; Young Wan Ham; Youngsoo Kim; Sang Bae Han; Mi Hee Park; Jin Tae Hong Journal: Redox Biol Date: 2017-04-05 Impact factor: 11.799
Authors: Ji Yeon Choi; Chul Ju Hwang; Do Yeon Lee; Sun Mi Gu; Hee Pom Lee; Dong Young Choi; Ki Wan Oh; Sang-Bae Han; Jin Tae Hong Journal: Neuromolecular Med Date: 2017-10-19 Impact factor: 3.843
Authors: Dong Ju Son; Jie Zheng; Yu Yeon Jung; Chul Ju Hwang; Hee Pom Lee; Ju Rang Woo; Song Yi Baek; Young Wan Ham; Min Woong Kang; Minho Shong; Gi Ryang Kweon; Min Jong Song; Jae Kyung Jung; Sang-Bae Han; Bo Yeon Kim; Do Young Yoon; Bu Young Choi; Jin Tae Hong Journal: Theranostics Date: 2017-10-16 Impact factor: 11.556